더보기Moderna surged 177% following positive Phase 3 cancer vaccine data with Merck. Here is what the topline trial results prove, what remains unverified, and why Wall Street repriced the mRNA oncology platform.Moderna’s 177% single-day surge was not driven merely by the commercial potential of a single melanoma therapy, but by the first late-stage clinical validation of its individualized mRNA on..
